Cysteinyl leukotrienes (cysLTs: LTC4, LTD4 and LTE4) are potent allergic mediators released from various inflam matory cells such as mast cells and eosinophils (1) . The action of cysLTs is mediated by their specific receptors that trigger activation/recruitment of inflammatory cells, enhancement of mucous secretion, vascular permeability and smooth-muscle tone (reviewed in ref. 2) . Because of these activities, cysLTs have been implicated in allergic rhinitis (3) . Recent human studies have shown that nasal provocation of LTD4 induce rhinorrhea and nasal congestion, as indicated by increases in nasal secretion and nasal airway resistance (NAR). The threshold concen tration of LTD4 required to induce these symptoms is approximately 5000-fold lower than that of histamine, a known mediator of allergic rhinitis (4) . Increased cys LTs have also been demonstrated in nasal lavage fluid in patients with allergic rhinitis after antigen provocation (5) . These studies further support the involvement of cysLTs in allergic rhinitis.
Although it is hypothesized that cysLTs participate in allergic rhinitis via a receptor-mediated mechanism, con vincing evidence has yet to be establised. were diluted with assay buffer as described below. For the in vivo study, LTD4 and histamine were diluted with 1/15 M of phosphate-buffered saline (PBS, pH 7.4) and saline, respectively. Pranlukast and epinastine for the binding study were initially dissolved in dimethylsulfoxide and diluted serially with the assay buffer. For oral admin istration, drugs were suspended in 0.5% carboxymethyl cellulose.
Preparation of nasal mucosa membranes in guinea pigs
Membrane fractions of guinea pig nasal mucosa were prepared by a previously described method (6) with slight modification. Briefly, animals were decapitated and nasal mucosae were removed. The tissues were dissected on ice, weighed and washed twice with 25 ml of ice-cold 1115 M PBS (pH 7.4). The tissues were then suspended in 5 vol. of 10 mM HEPES-NaOH/0.25 M sucrose buffer (pH 7.4) containing protease inhibitors (2 mM EDTA 4Na, 100 pg/ml soybean trypsin inhibitor, 100 pg/ml bacitracin, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, 0.01 mM leupeptin hemisulfate salt and 0.01 mM pep statin A). Tissues were homogenized thrice on ice by a Physcotron (Niti-on, Chiba) at 21,000 rpm for 20 sec. After centrifuging the homogenate (1,500 x g for 15 min at 41C), the supernatant was collected and subjected to higher centrifugation (40,000 X g for 30 min at 41C). The pellet was resuspended in 10 mM HEPES-NaOH buffer (pH 7.4) with a final protein concentration of 10 mg/ml and stored at 80'C until use. Protein concentrations were determined by the method of Lowry.
Radioligand binding study
The binding study was carried out in 10 mM HEPES NaOH buffer (pH 7. 
Nasal symptoms and nasal eosinophil infiltration
Various concentrations of 20 p1 LTD4 or histamine so lution were dripped into each nostril of either conscious or anesthetized normal guinea pigs and changes in nasal symptoms (NAR, nasal secretion and sneezing) and nasal eosinophil infiltration were observed as described below. All experiments were performed in an air-conditioned room.
NAR: Conscious animals were placed in a transparent body chamber and challenged with LTD4 as described above. Using non-invasive respiratory measurements (Buxco Electronics, Inc., Sharon, CT, USA), the total airway resistance (TAR) measured by the double flow plethysmograph technique (8) was considered as the NAR (9). The change was measured at 0, 10, 20 and 30 min post-challenge.
Nasal secretion: The surgically exposed trachea of animals, anesthetized with sodium nembutal (30 mg/kg, i.p.), were incisioned and a cannula was inserted in the lung-side section to maintain spontaneous respiration. Another cannula was inserted in the nasal-side section. At 10, 20 and 30 min post-challenge, cotton threads (weigh ing approximately 10 mg, 3-cm-long and 1-mm-diameter) were placed in both nostrils and nasal secretion was flushed out with compressed air-flow from the trachea to nostrils for 1 min. After flushing, weight increases of the threads due to nasal secretion were quantitatively evalu ated as nasal secretion.
Sneezing: Conscious animals were challenged with LTD4 as described above. The frequency of sneezing was counted at 10-min intervals for 30 min after the challenge of mediators.
Eosinophil infiltration: Conscious animals were challenged with LTD4 or histamine as described above. Animals were sacrificed by transection of the abdominal aorta under urethane anesthesia (50 mg/kg, i.p.) at vari ous times after post-challenge, and a cannula was inserted in the nasal side-section for nasal lavage. Nasal cavities were washed five times with 5 ml of saline containing 0.1% bovine serum albumin and the nasal lavage fluid (NLF) was collected. The NLF was centrifuged at 100 x g for 10 min at 4°C . Centrifuged, cell-pellets were suspend ed in 0.5 ml saline containing 0.1 % bovine serum albu min. Cells were then smeared on glass slides from aliquots of cell suspension with cytocentrifuge (50 x g, 5 min, room temperature) before staining with May-Grundwald Geimsa solution for eosinophil count under light microscopy.
Drug administration
Pranlukast and epinastine were orally administered 1 hr before LTD4 challenge in animals fasted overnight.
Statistical analyses
Data from the radioligand binding assay were subject ed to computer analysis using programs of Equilibrium Binding Data Analysis (EBDA by McPherson, Elsevier BIOSOFT, 1983). The equilibrium dissociation constant (Kd) and the maximum number of binding sites (Bm) were determined by Scatchard plot analysis of the satu ration binding data. The competitive activities of the analogues were expressed as the inhibition constant (K;), defined as K; = IC50 / (1 + [3H]cysLTs / Kd), where [3H] cysLTs was the concentration of radioligand used. All data were expressed as the mean ±S.E.M. Statistical sig nificance was determined either by Student's t-test or one-way analysis of variance followed by Dunnett's t test. P values of less than 0.05 were considered to be sig nificantly different. 
Effects of LTD4 on nasal symptoms
A preliminary time-course study showed that LTD4 challenge (3 pg/site) transiently increased both NAR and nasal secretion, with these levels returning to the basal level within the subsequent 20 min and no changes were observed at least until 8 hr after the challenge. However, whereas nasal secretion peaked at 10 min post-challenge, NAR peaked 10 to 20 min post-challenge. Therefore we compared the area under the curve (AUC) of NAR from 0 to 30 min post-challenge and amount of nasal secretion at 10 min post challenge in the subsequent experiments. As shown in Fig. 1 , nasal LTD4 challenge concentration dependently increased both NAR and nasal secretion significantly at concentrations higher than 10 pg/site and 1 pg/site, respectively, in normal guinea pigs. The respec tive increases in NAR and nasal secretion were approxi mately 3 and 2-fold at the highest concentration when compared with those of animals treated with vehicle. The challenge, however, did not induce sneezing even at 30 pg/site (5.3±1.0 counts vs 8.5--h1.4 counts in vehicle and LTD4, respectively, during the first 10 min after the challenge).
Effects of L TD4 and histamine on nasal inflammatory cell infiltration Nasal LTD4 (30 pg/site) challenge time-dependently in creased eosinophil counts in NLF. The infiltration peaked at 8 hr and persisted for not less than 24 hr after the challenge. Histamine, in contrast, did not have such an effect even at 3 mg/site within the experimental period (Fig. 2) . A concentration-response study showed that the response of LTD4 (1-30 pg/site) at 8 hr after post challenge was concentration-dependent, with significant responses at concentrations higher than 3 pg/site (Fig. 3) . Although lymphocyte counts were also significantly increased at the highest concentration of LTD, (1.75 ± 0.33 x 104 and 5.44 ± 1.30 x 104 cell/NLF in vehi cle and LTD4 challenge, respectively; P < 0.01 with Dun nett's t-test), no concentration-responses were observed in the total cells, neutrophils or macrophages.
Effects of pranlukast on LTD4-induced nasal symptoms
Nasal LTD4 (10 pg and 1 pg/site for NAR and nasal secretion, respectively) challenge significantly increased AUC of NAR from 0 to 30 min post-challenge and nasal secretion at 10 min post-challenge in normal guinea pigs. These changes were reduced by oral administrations of pranlukast (0.3 3 mg/kg) in a dose-dependent fashion with significant inhibitions at doses higher than 1 mg/kg in NAR and at 3 mg/kg in nasal secretion. However, these symptoms were not affected by an anti-histaminer gic, epinastine, even at 30 mg/kg (Fig. 4) , a dose that way sufficient to totally suppress histamine-induced responses (data not shown). 3 . Concentration-response of LTD4 on nasal eosinophil infiltration. Guinea pigs were nasally challenged with various concentrations of LTD4 and eosinophils in NLF at 8 hr post-challenge were counted as described in Fig. 2 . Each point represents the mean±S.E.M. of 9 to 10 animals. *P<0.05 and **P<0.01 vs vehicle (Dunnett's t-test). Fig. 4 . Effects of pranlukast and epinastine on LTD4-induced increases in NAR (A) and nasal secretion (B). Animals were nasally challenged with either 10 pg or 1 pg/site of LTD4 before NAR or nasal secretion were measured as described in Fig. 1 . Drugs were orally administered 1 hr before LTD4 challenge. #P < 0.05 and ##P < 0.01 vs vehicle (Student's t-test) and *P < 0.05 and **P<0.01 vs control (Dunnett's t-test).
Effects of pranlukast on LTD4-induced nasal eosinophil infiltration Nasal LTD4 (3 , tg/site) challenges significantly in creased eosinophil counts in NLF 8 hr after the challenge. This effect was inhibited by oral administrations of pran lukast (0.3 3 mg/kg) in a dose-dependent fashion. The suppression was significant at doses higher than 1 mg/kg. Epinastine (30 mg/kg, p.o.) did not affect the LTD4 induced change (Fig. 5) . 
DISCUSSION
This study shows that the membrane fraction of guinea pig nasal mucosae had specific binding sites for [3H]cys LTs, and rhinitis symptoms induced by nasal LTD4 challenge were abolished by a cysLT receptor antago nist, pranlukast.
These results support the current hypothesis that cysLTs are involved in allergic rhinitis via a receptor mediated mechanism.
The radioligand binding assay indicated the existence of a single class of high affinity and saturable binding sites for cysLTs in membrane fractions of the guinea pig nasal mucosa. These binding sites are cysLT receptors because pranlukast inhibited the binding of [3H]cysLTs to their specific binding sites in the nasal mucosa membrane. This is the first demonstration of the existence of cysLTs receptor in the nasal mucosa. It should be noted that Kd and Bmax values for [3H]LTC4i [3H]LTD4 and [3H]LTE4 in this study are similar to those previously reported with membrane fractions of guinea pig lung (6) . Therefore, it appears that the affinity and distribution of receptors for cysLTs is similar between upper and lower airways.
Analyses of Kd and Bmax values in our study indicate that LTD4 and LTE4 receptors had similar affinity and distribution, while LTC4 receptors displayed an affinity 60 to 140-fold lower and a density 30 to 80-fold higher than those of LTD4 and LTE4 in the guinea pig nasal mucosa, respectively. These findings are consistent with other biochemical (10) and pharmacological (11) studies and support the recent hypothesis that LTC4 receptor is biochemically different from LTD4 and LTE4 receptors (10) . The similarity in affinity and distribution between LTD4 and LTE4 receptors may be explained by the fact that LTE4 binds to a subset population of high-affinity LTD4 receptors (12) . Thus, LTC4 receptors may be differ ent from those of LTD4 and LTE4, although there is a possibility that LTD4 and LTE4 share the same binding site in guinea pig nasal mucosae.
In this study, we used LTD4 as a representative of cys LTs. Since LTC4 is rapidly converted to LTD4 and LTE4 by r-gultamyl transpeptidase (13) , it is very difficult to study the specific action of LTC4, LTD4 and LTE4, respectively, in vivo. Therefore, many investigators have used LTD4 in investigating actions of cysLTs (3). Although our study does not exclude a possible contribu tion of LTE4, it may be useful in understanding the ac tions of cysLTs.
Nasal LTD4 challenges significantly increased nasal secretion and NAR without inducing sneezing in normal guinea pigs. This observation is similar to that in an earlier human study (4) . On the other hand, while the threshold concentration in inducing these changes were different in this study, that in the human study is the same. This discrepancy may be attributed in large part to the condition of the recipients: we used anesthetized guinea pigs for nasal secretion and conscious guinea pigs for NAR while the investigators used conscious patients in the earlier study. The precise mechanism by which LTD4 induces these changes is unclear. However, it ap pears to be mediated by cysLTs receptor on nasal mu cosa, because these changes were abolished only by pran lukast but not by epinastine, which can antagonize the action of histamine, a known mediator to increase both nasal secretion and NAR (4) .
While the increase of NAR caused by LTD4 in this study was transient, peaking 10 to 20 min after the challenge, that in humans persisted for 8 hr after the challenge (4) . The discrepancy between these two results is unclear. This may be attributed to species differences, method for LTD4 challenge and/or subject condition (i.e., allergic or non allergic). In this study, LTD4 was nasally instilled into normal guinea pigs, whereas in the human study, LTD4-soaked paper discs were placed in the noses of patients with allergic rhinitis. Therefore, the longer contact period of LTD4 to the nasal mucosa and use of allergic recipient could have changed the NAR response of recipients to LTD4. In fact, it has been demonstrated that allergic persons have an enhanced sen sitivity to LTD4 (14) .
In addition to rhinitis symptoms, nasal eosinophil infiltration is one of the characteristics associated with al lergic rhinitis. We therefore studied if LTD4 caused nasal eosinophil infiltration. We found that nasal LTD4, but not histamine, challenge induced significant eosinophil infiltration into guinea pigs that persisted until 24 hr after LTD4 challenge. It has been reported that LTD4 (30 yg/ml) inhalation caused prolonged eosinophil infiltra tion into guinea pig lungs (15, 16) . These results collec tively suggest that LTD4 potently induces eosinophil infiltration. Since the infiltration was totally inhibited by pranlukast, the action is probably mediated by cysLT receptor as well. However, in contrast to another report (17) that LTD4 as low as 10-10M displays chemotactic activity against human eosinophils, we found that LTD4 up to 10 ,uM had no apparent chemotactic activity against guinea pig eosinophils in vitro (data not shown). There fore, induction of eosinophil infiltration is probably not a direct effect of LTD4 on guinea pig eosinophils. It is pos sible, however, that cells other than eosinophils and/or organs may produce eosinophil chemoatractant in response to LTD4 via a receptor-mediated mechanism. One of the candidate mediators would be thromboxane A2 (TXA2), because LTD4 induces TXA2 synthesis (18) , and TXA2 has been suggested to be associated with nasal eosinophil migration in a model of allergic rhinitis in guinea pigs (19) . Further studies are warranted to eluci date the mechanisms by which LTD4 induces eosinophil infiltration in vivo.
The symptoms of allergic rhinitis often display a biphasic pattern characterized by early-phase symptoms (sneezing, rhinorrhea and nasal obstruction) and late phase symptom (nasal congestion) accompanied by eo sinophil infiltration into nasal mucosae. Although the role of eosinophils in allergic rhinitis is not clear, it has been suggested that eosinophils are an important cellular source of chemical mediators, including cysLTs in the late-phase (20) . Our results suggest that cysLTs induce not only early-phase symptoms but also nasal eosinophil infiltration, a characteristic associated with the late phase, via cysLT receptor-mediated mechanisms. Since eosinophils are a cellular source of cysLTs (21), it may be rational to speculate that cysLTs production in the late phase is enhanced by eosinophil recruitment of cysLTs. This concept is supported by the fact that cysLTs are detectable in not only the early but the late-phase (5) as well. Therefore, in addition to induction of the early phase symptoms in allergic rhinitis, cysLTs may modulate events in the late-phase response.
In conclusion, as cysLTs induced symptoms typical of allergic rhinitis via a receptor-mediated mechanism, they may thus have an important role in allergic rhinitis.
